Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain. The congress is scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation underscores the company's ongoing commitment to advancing treatment options for fibromyalgia, a chronic condition affecting millions worldwide.
TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025. As the first new treatment for fibromyalgia in more than 15 years, TONMYA represents a significant milestone for patients who have had limited therapeutic innovation. The upcoming poster presentation at IASP will provide scientific evidence on how TONMYA impacts both symptom burden and physical function, potentially reinforcing its role in clinical practice. For full details, see the complete press release.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including acute migraine therapies Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, Tonix's pipeline includes TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for prevention of kidney transplant rejection. These candidates are investigational, and their efficacy and safety have not been established.
The IASP World Congress on Pain is a global forum that brings together researchers, clinicians, and industry leaders to discuss the latest advances in pain management. Presenting TONMYA data at this event may enhance awareness among healthcare professionals and potentially drive adoption. For investors, the presentation could serve as a catalyst by demonstrating the product's clinical profile. Latest updates on TNXP are available in the company's newsroom.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The full terms of use are available in the disclaimer.
